Thrombolytic Science International

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Thrombolytic Science International, LLC (TSI)
Private
Industry Biotechnology
Headquarters Cambridge, MA
Website [1]

Thrombolytic Science International (TSI) is a private biopharmaceutical company beginning Phase I clinical trials of TS01, a new-generation therapy to treat acute strokes and heart attacks.[1]

Tissue plasminogen activator (tPA) has remained the only clot-dissolving, thrombolytic drug available for clinical use in patients with ischemic stroke since its approval in 1996.[2] Only about 5% of stroke patients are treated with tPA because of its short treatment time-window, suboptimal efficacy, and risk of intra-cranial hemorrhage.[3]

TS01 is a clot-dissolving treatment consisting of a mutated form of the first-generation thrombolytic, pro-urokinase (pro-UK) preceded by a bolus of plasma complement 1 esterase inhibitor (C1-inhibitor).[4]

TS01 targets only the occlusive (bad) clots that lead to stroke, a fact which the company expects will significantly reduce the risk of bleeding. Like its parent molecule pro-UK, TS01 is also expected to show a longer treatment time-window than tPA. These attributes will allow many more patients to be treated with this potentially life-saving treatment.[5]

Peer-Reviewed Articles[edit]

References[edit]

  1. ^ Hay, Timothy. (12 January 2012). "With $7.5M, TSI Aims To Succeed Where Bat Spit, Snake Venom Failed." Dow Jones VentureWire.
  2. ^ Haas, Michael J.. (22 March 2012). "Monkeys bridge the stroke gap." SciBX.
  3. ^ Rhodes, Jennifer. (6 February 2012). "Specifying Stroke." BioCentury.
  4. ^ Haas, Michael J.. (22 March 2012). "Monkeys bridge the stroke gap." SciBX.
  5. ^ Rhodes, Jennifer. (6 February 2012). "Specifying Stroke." BioCentury.

External links[edit]